tiprankstipranks
Tango Therapeutics (TNGX)
NASDAQ:TNGX
US Market
Holding TNGX?
Track your performance easily

Tango Therapeutics (TNGX) Income Statement

302 Followers

Tango Therapeutics Income Statement

Last quarter (Q3 2024), Tango Therapeutics's total revenue was $11.61M, an increase of 8.15% from the same quarter last year. In Q3, Tango Therapeutics's net income was $-29.17M. See Tango Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21
Total Revenue
$ 43.38M$ 36.53M$ 24.86M$ 37.04M
Cost of Revenue
----
Gross Profit
$ 43.38M$ 36.53M$ 24.86M$ 37.04M
Operating Expense
$ 183.08M$ 150.70M$ 135.93M$ 95.23M
Operating Income
$ -139.70M$ -114.17M$ -111.07M$ -58.19M
Net Non Operating Interest Income Expense
$ 8.31M$ 6.62M$ 1.46M$ 495.00K
Other Income Expense
$ 6.15M$ 5.94M$ 1.49M$ 1.03M
Pretax Income
$ -124.69M$ -101.61M$ -108.12M$ -57.94M
Tax Provision
$ 206.00K$ 134.00K$ 54.00K$ 292.00K
Earnings From Equity Interest Net Of Tax
----
Net Income Common Stockholders
$ -123.47M$ -101.74M$ -108.18M$ -58.23M
Basic EPS
$ -1.16$ -1.08$ -1.23$ -0.94
Diluted EPS
$ -1.16$ -1.08$ -1.23$ -0.94
Basic Average Shares
$ 429.70M$ 94.57M$ 87.82M$ 62.11M
Diluted Average Shares
$ 429.70M$ 94.57M$ 87.82M-
Dividend Per Share
----
Total Operating Income As Reported
----
Reported Normalized Basic E P S
----
Reported Normalized Diluted E P S
----
Rent Expense Supplemental
----
Total Expenses
$ 183.08M$ 150.70M$ 135.93M$ 95.23M
Net Income From Continuing And Discontinued Operation
$ -123.39M$ -101.74M$ -108.18M$ -58.23M
Normalized Income
$ -79.51M$ -80.27M--
Interest Expense
----
EBIT
$ -134.01M$ -114.17M$ -111.07M$ -58.19M
EBITDA
$ -128.70M$ -111.76M$ -109.46M$ -57.29M
Currency in USD

Tango Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis